191 related articles for article (PubMed ID: 30412444)
1. Elimination or neutralization of endogenous high-molecular-weight FGF2 mitigates doxorubicin-induced cardiotoxicity.
Koleini N; Santiago JJ; Nickel BE; Sequiera GL; Wang J; Fandrich RR; Jassal DS; Dhingra S; Kirshenbaum LA; Cattini PA; Kardami E
Am J Physiol Heart Circ Physiol; 2019 Feb; 316(2):H279-H288. PubMed ID: 30412444
[TBL] [Abstract][Full Text] [Related]
2. Elimination of endogenous high molecular weight FGF2 prevents pressure-overload-induced systolic dysfunction, linked to increased FGFR1 activity and NR1D1 expression.
Koleini N; Nickel BE; Nagalingam RS; Landry NM; Fandrich RR; Cheung DYC; Dixon IM; Czubryt MP; Jassal DS; Cattini PA; Kardami E
Cell Tissue Res; 2021 Sep; 385(3):753-768. PubMed ID: 34057573
[TBL] [Abstract][Full Text] [Related]
3. Non-mitogenic FGF2 protects cardiomyocytes from acute doxorubicin-induced toxicity independently of the protein kinase CK2/heme oxygenase-1 pathway.
Koleini N; Nickel BE; Edel AL; Fandrich RR; Ravandi A; Kardami E
Cell Tissue Res; 2018 Dec; 374(3):607-617. PubMed ID: 30159756
[TBL] [Abstract][Full Text] [Related]
4. High molecular weight fibroblast growth factor-2 in the human heart is a potential target for prevention of cardiac remodeling.
Santiago JJ; McNaughton LJ; Koleini N; Ma X; Bestvater B; Nickel BE; Fandrich RR; Wigle JT; Freed DH; Arora RC; Kardami E
PLoS One; 2014; 9(5):e97281. PubMed ID: 24827991
[TBL] [Abstract][Full Text] [Related]
5. Preferential accumulation and export of high molecular weight FGF-2 by rat cardiac non-myocytes.
Santiago JJ; Ma X; McNaughton LJ; Nickel BE; Bestvater BP; Yu L; Fandrich RR; Netticadan T; Kardami E
Cardiovasc Res; 2011 Jan; 89(1):139-47. PubMed ID: 20696821
[TBL] [Abstract][Full Text] [Related]
6. Rosmarinic acid alleviates cardiomyocyte apoptosis via cardiac fibroblast in doxorubicin-induced cardiotoxicity.
Zhang X; Zhu JX; Ma ZG; Wu HM; Xu SC; Song P; Kong CY; Yuan YP; Deng W; Tang QZ
Int J Biol Sci; 2019; 15(3):556-567. PubMed ID: 30745842
[TBL] [Abstract][Full Text] [Related]
7. Cardiac Fgf-16 Expression Supports Cardiomyocyte Survival and Increases Resistance to Doxorubicin Cytotoxicity.
Wang J; Xiang B; Dolinsky VW; Kardami E; Cattini PA
DNA Cell Biol; 2018 Nov; 37(11):866-877. PubMed ID: 30230915
[TBL] [Abstract][Full Text] [Related]
8. Expression of the Cardiac Maintenance and Survival Factor FGF-16 Gene Is Regulated by Csx/Nkx2.5 and Is an Early Target of Doxorubicin Cardiotoxicity.
Wang J; Jin Y; Cattini PA
DNA Cell Biol; 2017 Feb; 36(2):117-126. PubMed ID: 27929351
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor-2-mediated protection of cardiomyocytes from the toxic effects of doxorubicin requires the mTOR/Nrf-2/HO-1 pathway.
Koleini N; Nickel BE; Wang J; Roveimiab Z; Fandrich RR; Kirshenbaum LA; Cattini PA; Kardami E
Oncotarget; 2017 Oct; 8(50):87415-87430. PubMed ID: 29152091
[TBL] [Abstract][Full Text] [Related]
10. A Cardiac Mitochondrial FGFR1 Mediates the Antithetical Effects of FGF2 Isoforms on Permeability Transition.
Srisakuldee W; Nickel BE; Fandrich RR; Zhang F; Pasumarthi KBS; Kardami E
Cells; 2021 Oct; 10(10):. PubMed ID: 34685716
[TBL] [Abstract][Full Text] [Related]
11. Exercise during pregnancy decreases doxorubicin-induced cardiotoxic effects on neonatal hearts.
Brito VB; Nascimento LV; Nunes RB; Moura DJ; Lago PD; Saffi J
Toxicology; 2016 Aug; 368-369():46-57. PubMed ID: 27565713
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor counteracts Doxorubicin-induced cardiotoxicity in male mice.
Ikeda Y; Aihara K; Akaike M; Sato T; Ishikawa K; Ise T; Yagi S; Iwase T; Ueda Y; Yoshida S; Azuma H; Walsh K; Tamaki T; Kato S; Matsumoto T
Mol Endocrinol; 2010 Jul; 24(7):1338-48. PubMed ID: 20501642
[TBL] [Abstract][Full Text] [Related]
13. Cardiomyocytes, cardiac endothelial cells and fibroblasts contribute to anthracycline-induced cardiac injury through RAS-homologous small GTPases RAC1 and CDC42.
Kücük P; Abbey L; Schmitt J; Henninger C; Fritz G
Pharmacol Res; 2024 May; 203():107165. PubMed ID: 38561112
[TBL] [Abstract][Full Text] [Related]
14. Loss of Mrp1 Potentiates Doxorubicin-Induced Cytotoxicity in Neonatal Mouse Cardiomyocytes and Cardiac Fibroblasts.
Zhang W; St Clair D; Butterfield A; Vore M
Toxicol Sci; 2016 May; 151(1):44-56. PubMed ID: 26822305
[TBL] [Abstract][Full Text] [Related]
15. Nrf2 deficiency exaggerates doxorubicin-induced cardiotoxicity and cardiac dysfunction.
Li S; Wang W; Niu T; Wang H; Li B; Shao L; Lai Y; Li H; Janicki JS; Wang XL; Tang D; Cui T
Oxid Med Cell Longev; 2014; 2014():748524. PubMed ID: 24895528
[TBL] [Abstract][Full Text] [Related]
16. Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin.
Li K; Sung RY; Huang WZ; Yang M; Pong NH; Lee SM; Chan WY; Zhao H; To MY; Fok TF; Li CK; Wong YO; Ng PC
Circulation; 2006 May; 113(18):2211-20. PubMed ID: 16651473
[TBL] [Abstract][Full Text] [Related]
17. Sodium thiosulfate prevents doxorubicin-induced DNA damage and apoptosis in cardiomyocytes in mice.
Mizuta Y; Tokuda K; Guo J; Zhang S; Narahara S; Kawano T; Murata M; Yamaura K; Hoka S; Hashizume M; Akahoshi T
Life Sci; 2020 Sep; 257():118074. PubMed ID: 32673667
[TBL] [Abstract][Full Text] [Related]
18. Phosphoinositide 3-Kinase Gamma Inhibition Protects From Anthracycline Cardiotoxicity and Reduces Tumor Growth.
Li M; Sala V; De Santis MC; Cimino J; Cappello P; Pianca N; Di Bona A; Margaria JP; Martini M; Lazzarini E; Pirozzi F; Rossi L; Franco I; Bornbaum J; Heger J; Rohrbach S; Perino A; Tocchetti CG; Lima BHF; Teixeira MM; Porporato PE; Schulz R; Angelini A; Sandri M; Ameri P; Sciarretta S; Lima-Júnior RCP; Mongillo M; Zaglia T; Morello F; Novelli F; Hirsch E; Ghigo A
Circulation; 2018 Aug; 138(7):696-711. PubMed ID: 29348263
[TBL] [Abstract][Full Text] [Related]
19. Cardamonin protects against doxorubicin-induced cardiotoxicity in mice by restraining oxidative stress and inflammation associated with Nrf2 signaling.
Qi W; Boliang W; Xiaoxi T; Guoqiang F; Jianbo X; Gang W
Biomed Pharmacother; 2020 Feb; 122():109547. PubMed ID: 31918264
[TBL] [Abstract][Full Text] [Related]
20. FGF-2 protects cardiomyocytes from doxorubicin damage via protein kinase C-dependent effects on efflux transporters.
Wang J; Nachtigal MW; Kardami E; Cattini PA
Cardiovasc Res; 2013 Apr; 98(1):56-63. PubMed ID: 23341575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
